Celldex Therapeutics, Inc. - Common Stock (NQ:CLDX)

38.02 -1.16 (-2.96%)

Streaming Delayed Price Updated: 11:00 AM EDT, Sep 15, 2026 Add to My Watchlist

Price and Volume

Volume	147,624
Open	39.00
Bid (Size)	37.96 (100)
Ask (Size)	38.02 (100)
Prev. Close	39.18
Today's Range	37.74 - 39.19
52wk Range	22.10 - 45.14
Shares Outstanding	66,344,236
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Celldex to Present at Upcoming Investor Conference

September 08, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Therapeutics (NASDAQ:CLDX) Q2 EPS Beat Overshadowed by Revenue Miss and Prurigo Nodularis Discontinuation ↗

August 06, 2026

Via Chartmill

Performance

YTD	+40.8%	+40.8%
1 Month	-9.3%	-9.3%
3 Month	+18.4%	+18.4%
6 Month	+25.9%	+25.9%
1 Year	+55.2%	+55.2%

More News

Celldex Reports Second Quarter Financial Results and Provides Corporate Update

August 06, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Therapeutics Scraps PN Plans After Barzolvolimab Phase 2 Miss ↗

July 22, 2026

Via MarketBeat

Celldex Reports Results from Phase 2 Study of Barzolvolimab in Prurigo Nodularis

July 21, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Therapeutics Inc (NASDAQ:CLDX) Shows Strong Technical Breakout Setup ↗

May 14, 2026

Via Chartmill

Celldex Announces Planned Transition of Chief Financial Officer

July 15, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now ↗

June 19, 2026

Via InvestorPlace

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

June 14, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

June 14, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

June 10, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Curious about the stocks that are showing activity after the closing bell on Tuesday? ↗

May 19, 2026

Via Chartmill

Celldex Reports First Quarter Financial Results and Provides Corporate Update

May 07, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex to Present at Upcoming Investor Conference

April 13, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

April 06, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Announces Pricing of $300 Million Public Offering of Common Stock

April 01, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Announces Proposed Public Offering of Common Stock

April 01, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026

March 27, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest Holding ↗

March 21, 2026

Via The Motley Fool

This Fund Just Cut a Viridian Stock Position by Over $80 Million. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

This Biotech Stock Up 135% Just Faced a $44 Million Trim. Here's What Investors Should Know ↗

March 21, 2026

Via The Motley Fool

Biotech Stock Up 72% Sees $8 Million Sale, but Here's Why One Fund Still Seems Bullish ↗

March 21, 2026

Via The Motley Fool

Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease

March 01, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at

February 27, 2026

From Celldex Therapeutics, Inc.

Via GlobeNewswire

CLDX Soars On Bullish Timelines For Urticaria Clinical Program: Retail Sees Experimental Skin Treatment’s Sales Beat Big Pharma’s Dupixent ↗

February 25, 2026

Via Stocktwits

Frequently Asked Questions

Is Celldex Therapeutics, Inc. - Common Stock publicly traded?

Yes, Celldex Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Celldex Therapeutics, Inc. - Common Stock trade on?

Celldex Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Celldex Therapeutics, Inc. - Common Stock?

The ticker symbol for Celldex Therapeutics, Inc. - Common Stock is CLDX on the Nasdaq Stock Market

What is the current price of Celldex Therapeutics, Inc. - Common Stock?

The current price of Celldex Therapeutics, Inc. - Common Stock is 38.02

When was Celldex Therapeutics, Inc. - Common Stock last traded?

The last trade of Celldex Therapeutics, Inc. - Common Stock was at 09/15/26 11:00 AM ET

What is the market capitalization of Celldex Therapeutics, Inc. - Common Stock?

The market capitalization of Celldex Therapeutics, Inc. - Common Stock is 2.52B

How many shares of Celldex Therapeutics, Inc. - Common Stock are outstanding?

Celldex Therapeutics, Inc. - Common Stock has 3B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.